GLP-1 Medications Revolutionize Obesity Treatment, Study Shows GLP-1 receptor agonists, including semaglutide-based drugs like Ozempic and Wegovy, have significantly improved weight management outcomes, according to a 2023 meta-analysis published in …
Tag:
Eli Lilly
-
-
Employers are increasingly implementing stricter requirements for GLP-1 receptor agonist coverage, often mandating verified weight-loss progress or participation in health coaching programs before approving long-term prescriptions. These policies reflect a …
-
The Rising Tide of Digital Disinformation: Protecting Human Rights in the Modern Era In an increasingly interconnected world, the integrity of public discourse is under constant threat. As digital platforms …
-
Breakthrough in Gene-Editing Therapy for Cholesterol Reduction Verve Therapeutics has announced encouraging results from its Phase 1b clinical trial of VERVE-102, a gene-editing therapy targeting PCSK9 to lower LDL-C, or …
-
Health
25, Takeda Pharmaceutical, Tokyo, Japan, Broad Pharmaceuticals, Global Giant; 26, Daiichi Sankyo, Tokyo, Japan, Cardiovascular, Oncology, Global Major
Takeda Pharmaceuticals: Advancing Healthcare Innovation from Tokyo, Japan Takeda Pharmaceutical Company Limited stands as a global biopharmaceutical leader headquartered in Tokyo, Japan, with a legacy spanning over 230 years. The …
-
Alzheimer’s Diagnosis in Her 30s Sparks Insurance Battle Alzheimer’s disease is often associated with older adults, but a Massachusetts woman, Haritha Sudanagunta, received a devastating diagnosis in her thirties. Her …
-
Next-Generation Weight-Loss Drugs Show Promise in Clinical Trials The landscape of weight-loss medication is rapidly evolving, with new drugs demonstrating significant results in clinical trials. Eli Lilly’s retatrutide, a next-generation …
-
S&P Upgrades Ireland’s Credit Rating to AA+, Nearing AAA Status S&P Global Ratings has upgraded Ireland’s sovereign credit rating to AA+, bringing the country within one notch of a top-tier …
-
Trump’s Drug Pricing Deals: Three-Year Terms Revealed in SEC Filings WASHINGTON — President Trump’s “most-favored nation” (MFN) deals with pharmaceutical companies, touted as a way to lower prescription drug costs …
-
Trump’s “Liberation Day” Tariffs: A Year of Unexpected Economic Resilience When Donald Trump famously announced his “Liberation Day” tariff assault on the world in April 2025, economists widely predicted a …
Newer Posts